Peripheral nerve tumors comprise both benign and malignant variants. Benign tumors are predominantly either schwannomas or neurofibromas. The former represent approximately 5% of all benign tumors of the soft tissue. Absence of the NF2 gene is required for tumor development. This information and related findings have served as a nidus for research aimed at more fully characterizing this family of conditions. Recent discoveries in the laboratory have clarified an understanding of the molecular mechanisms underlying the pathogenesis of benign peripheral nerve tumors. Similarly, the mechanisms whereby idiopathic and syndromic (NF1- and NF2-associated) nerve sheath tumors progress to malignancy are being elucidated. This detailed understanding of the molecular pathogenesis of peripheral nerve tumors provides the information necessary to create a new generation of therapies tailored specifically to the prevention, cessation, or reversal of pathological conditions at the fundamental level of dysfunction. The authors review the data that have helped to elucidate the molecular pathogenesis of this category of conditions, explore the current progress toward exploitation of these findings, and discuss potential therapeutic avenues for future research.

Keywords • experimental therapy • malignancy • neurofibroma • schwannoma • tumor

Abbreviations used in this paper: ATP = adenosine 5’ triphosphate; bFGF = basic fibroblast growth factor; EGF = epidermal growth factor; ER = ezrin-radixin-moesin; FGF = fibroblast growth factor; FTI = farnesyl transferase inhibitor; GAP = GTPase associated protein; GDP = guanosine diphosphate; GEF = guanine nucleotide exchange factor; GRD = GAP-related domain; GTP = guanosine triphosphate; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; HSV = herpes simplex virus; LOH = loss of heterozygosity; MAPK = mitogen-activated protein kinase; MK = midkine; MPNST = malignant peripheral nerve sheath tumor; mTOR = mammalian target of rapamycin; NF = neurofibromatosis; NF1 = NF Type 1; NF2 = NF Type 2; NIH = National Institutes of Health; NGF = nerve growth factor; PDGF = platelet-derived growth factor; PI3K = phosphoinositide 3-kinase; Raf = Ras activated factor; SCF = stem cell factor; TGF = transforming growth factor; VCAM = vascular cell adhesion molecule; VEGF = vascular endothelial growth factor; VEGFR-2 = VEGF receptor 2.
last category that MPNSTs arise. Despite a low overall incidence of NF1 in the general population, over half of the patients with MPNSTs have NF1. The results of a recent study demonstrated a 5-year postdiagnosis survival of approximately 52% in patients with MPNSTs. Current treatment strategies for peripheral nerve tumors include observation, incisional biopsy, and surgical or nonoperative management through the use of radio- or chemotherapy. Benign idiopathic schwannomas and neurofibromas are unlikely to become malignant, so in the presence of advanced age, minimal symptomatology, and little evidence of progression on imaging studies, it is appropriate to consider conservative therapies. At the opposite end of the spectrum, malignant peripheral nerve tumors are of only intermediate chemosensitivity, are often associated with the presence of clinical symptoms such as pain at rest, display a high rate of progression on imaging studies, and are associated with a high mortality rate. Therefore, surgical attempts to fully resect the tumor mass, when in the presence of a systemic condition (for example, NF1), are required. Unfortunately, despite the advent of improvements in intraoperative microsurgical technique, resection is not a curative approach for malignant peripheral nerve tumors; these tumors continue to pose a significant challenge to practicing physicians. The best results are currently achieved through a close collaboration of allied professionals in a multidisciplinary team to achieve a resection with adequate margins. Standard therapeutic principles are covered in greater depth elsewhere in this issue. Herein, we review the data that has helped to elucidate the molecular pathogenesis of this category of conditions, explore the current progress toward exploitation of these findings, and discuss potential therapeutic avenues for future research.

Molecular Pathogenesis

The discovery that the Schwann cell is the primary cell type responsible for both the neurofibroma as well as the schwannoma has proven to represent a crucial milestone in understanding the pathogenesis of peripheral nerve tumor development. This information and related findings have served as a nidus for research aimed at characterizing this family of conditions. To date, research efforts have delineated unique gene mutations responsible for each tumor type, elements of the contributory molecular pathways, factors that contribute to malignant progression, and modifying effects of known neurogenetic conditions and mutations on the clinically observed disease course. The following paragraphs focus on recent findings that have clarified the complex molecular interplay responsible for tumor development, specifically discussing neurofibroma, schwannoma, and the elements important for progression to malignancy. The current discussion excludes secondary tumors, hemangiomas arising from capillaries, and ganglion tumors arising from the sympathetic nervous system (for example, ganglioneuromas and ganglioneuroblastomas). Figure 1A summarizes the present knowledge of the distinct but related molecular mechanisms responsible for tumorigenesis, while Fig. 1B emphasizes the critical role of neurofibromin and merlin in the dysregulation of intracellular pathways respectively responsible for neurofibroma and schwannoma development.

The Role of Neurofibromin. The NF1 locus, present at 17q11.2, has an overall genomic size of approximately 350 kb spread across 60 exons. It was initially recognized and isolated as the gene responsible for development of NF1, an autosomal neurogenetic condition responsible for a wide range of cutaneous and systemic sequelae. In addition to the primary transcript, the NF1 gene locus contains an additional three genes within the span of exon 27 and a pseudogene within intron 37. Specifically, it is localized to the cytoplasm and has been colocalized with microtubules. Expression is present during embryological development and reaches adult levels after 1 week of postnatal life. Physiologically, neurofibromin has been shown to play an important upstream role as a negative regulator of the mitogen signal transduction cascade mediated by p21-Ras.

Multiple classes of extracellular mitogens or growth factors activate transmembrane receptor tyrosine kinase signaling proteins that are phosphorylated on intracytoplasmic domains and, in turn, activate intracellular GEF proteins. Activated GEF proteins result in exchange of GDP for GTP on the membrane-associated Ras protein. The now-activated Ras-GTP is capable of interacting with effectors of unique but related downstream signaling cascades that promote the broad cellular end points of proliferation and apoptosis inhibition. Specifically, activated Ras-GTP is known to act through two predominant signaling pathways: Ras/PI3K and the Ras/Raf (Ras-activated factor)/MAPK pathway. The Ras/PI3K pathway achieves antiapoptotic effects divergently through NF1, while the latter helps to stabilize mediators of the cytoplasmic apoptotic response. An additional Ras/PI3K-mediated pathway downstream of Akt, mTOR, has recently been demonstrated to be constitutively upregulated in the absence of neurofibromin. This pathway, known widely to play a role in malignant cell growth, is exquisitively sensitive to rapamycin-related agents. Further, these initial studies have indicated that tumor-derived cell lines are responsive to rapamycin. Cell proliferation is promoted by Raf kinase activation and nuclear transduction through activation of Mek, Erk1, and Erk2 MAPK isoforms. Neurofibromin acts as a physiological counterbalance, inhibiting these downstream effectors through inhibition of the activated Ras protein following clearance of extracellular signaling molecules. Activation of intrinsic Ras GTPase functionality, by a GTPase-related domain present on neurofibromin, results in cleavage of GTP to GDP and subsequent inactivation of the Ras protein. Therefore, neurofibromin acts
as a negative regulator of separate proliferative and cell survival pathways through upstream inhibition of Ras-mediated signaling.

The central role played by Ras in the balance of cell growth and survival underscores the importance of disturbances in the Ras pathway. Its dysregulation has been implicated as a contributor to cancer development. More specifically, constitutively upregulated Ras activity, as in the absence of neurofibromin, has been demonstrated to contribute to a range of human cancers. Homozygous loss of neurofibromin, a condition promoted in the context of the inherited condition NF1, represents the central requirement for tumor development. However, definitive demonstration has required construction of elegant experiments, in part because the neurofibroma tumor microenvironment is heterogeneous, containing Schwann cells, perineural cells, endothelial cells, mast cells, and fibroblasts. Because the NF1 gene is required for embryological development, the potential for use of an NF1 knockout animal model is abrogated. Further, heterozygosity does not predispose mice to tumor development. Le and Parada have addressed this issue by hypothesizing that the lack of correlation with the human condition may result from a smaller neural crest compartment and shorter gestation time in the mouse model. Therefore, use of a conditional knockout in an otherwise NF1+− animal model has been necessary to create Schwann cells lacking both copies of neurofibromin with consequent tumor development. Specifically, the Cre/lox system is employed; Cre is a recombinase that recognizes the short loxP sequences. Thus, the induction of Cre expression in Schwann cells that contain a single copy of neurofibromin flanked by loxP sites results in the removal of the intervening neurofibromin gene and the recombination of the flanking ends. This approach creates an experimental tool that allows conditional suppression of desired genes and has been used to demonstrate that the presence of NF1−− Schwann cells is sufficient to promote schwannoma formation in an otherwise heterozygous animal. This finding has been corroborated more recently by implantation of NF1-deficient Schwann cells into the nerve of an animal model heterozygous for NF1. Further, the tumorigenic potential is recapitulated when heterozygosity is limited to the local microenvironment, providing evidence for complex feedback mechanisms within this niche.

Mechanisms for Tumor Development. Because homozygous loss of functional protein is required for tumor development, it may be expected that a germline mutation precedes a second somatic event in the majority of cases. The autosomal dominant disorder NF1 represents the occur-
rence of such a germline mutation. In the case of isolated neurofibromas, the first mutation probably occurs during the late embryonic period or during early fetal development. The second event, in all cases a somatic mutation, may or may not result in LOH but does result in loss of functional protein. A wide range of mutation types have been observed to occur at the NF1 locus. In particular, nondisjunction, somatic recombination, and large intragenic deletions may result in LOH. However, loss of protein function may also occur due to the presence of mutations in the intron sequences, altering peptide splicing; the promoter regions controlling expression; or in sequences that repress expression through alteration of methylation patterns. It is important to point out that phenotype–genotype correlation between specific mutations and the clinical course has not been noted. Moreover, no specific predilection for any particular mutation has been noted, with only 7% of mutations having been observed more than once. The lack of phenotype–genotype correlation is probably attributable to both the temporal and anatomical heterogeneity of the mutation or “hit” to the second NF1 allele as well as to the lack of a conserved mutation event at a particular hot spot within the NF1 locus. Additionally, it could represent the presence of a “third hit” to a modifier of the pathogenic process. Modifiers could include proteins that directly or indirectly interact with Ras or alternatively proteins that contribute to tumorigenesis through modification of the local microenvironment.

Contributions of the Local Microenvironment. A large quantity of data implicates the NF1+/− Schwann cell as the initiator of a complex feedback mechanism occurring within the local microenvironment of tumor development. Specifically, a reduction in the presence of neurofibromin is thought to alter the balance of reciprocal feedback mechanisms that normally exist between the cells that constitute the local microenvironment of the peripheral nerve. The initial data generated by Zhu and colleagues, demonstrating neurofibroma development with the use of a Cre/lox conditional expression system, showed mast cell infiltration only when this cell type was heterozygous at the NF1 locus. Further, the mast cell infiltrate preceded tumor development. The results of tissue culture studies have subsequently confirmed a reciprocal feedback mechanism that is established between the homozygous null (NF1−/−) Schwann cell and the heterozygous (NF1+/−) mast cell in the tumor microenvironment. One result of constitutive p21-Ras activation is the increased secretion of the SCF, also known as kit ligand. Additionally, the authors demonstrated that the NF1 heterozygotic mast cell is both hypermotile and hyperproliferative in the presence of SCF. An increased ability to migrate to the tumor microenvironment requires binding of the mast cell αvβ3 integrin to the endothelial-derived VCAM-1 cell surface protein. More recently, the authors have demonstrated that the attracted mast cells secrete TGFβ when heterozygous for NF1 and in the presence of elevated SCF concentrations. In this study, TGFβ was demonstrated to act as a profibrotic agent when interacting with heterozygous fibroblasts present in the tumor microenvironment. Additionally, migrated mast cells are known to secrete NGF and VEGF, known stimulants of Schwann cell survival, proliferation, and migration as well as of increased neovascularization.

The NF1 heterozygous of endothelial cells has also been implicated as a contributor to neurofibroma neoangiogenesis. Wu et al. have recently demonstrated that NF1+/− endothelial cells undergo increased neovascularization when exposed to hypoxia and the angiogenic factor bFGF, as compared to wildtype littermates in a mouse model. Separately, Munchoff et al. have provided mouse in vitro and in vivo data corroborating these findings and implicating a Ras-dependent pathway, verified in tissue from a patient with NF1, in the process of neoangiogenesis. A wide variety of additional stimulatory autocrine and paracrine growth factors have been implicated as contributors to the tumor-promoting environment. Examples of such Schwann cell mitogens include: hepatocyte growth factor, bFGF, insulin growth factor−1, and MK. Further, Schwann cells upregulate secretion of FGF-2, PDGF, and MK when they lack a functioning neurofibromin gene.

In context, the data presented above indicate that a homozygous null NF1−/− Schwann cell is required as the nidus for tumor development. The formation of a neurofibroma is dependent upon the loss of expression of both functional copies of neurofibromin, through a minimum of two critical mutational events and a loss of neurofibromin expression within the already susceptible Schwann cell. In tandem, heterozygosity of the local microenvironment appears to carry an increased susceptibility to tumor transformation. The intracellular imbalance of the Ras-dependent pathways within the Schwann cell results in elevated secretion of growth factors that act in an autocrine and paracrine fashion, additionally promoting release of diffusible chemotactic agents such as SCF. Migration of NF1−/− mast cells to the local microenvironment augments the imbalance by promoting fibrosis, neoangiogenesis, and Schwann cell mitogenesis. Finally, other contributors may simultaneously facilitate the transformation cascade through release of additional putative growth factors.

Schwannoma Development

The Role of Merlin

The NF2 gene locus is at 22q12.2 and the gene encodes a protein variably known as merlin or schwannomin. For the sake of clarity, we will refer to this protein as merlin in this review. Like neurofibromin, merlin is required for embryological development. Deficiency of this protein, when localized to the Schwann cell, appears to be both necessary and sufficient to cause cellular transformation and schwannoma development. Heterozygosity at this locus predisposes individuals to development of NF2, an autosomal dominant condition predisposing afflicted individuals to the development of central nervous system (glioma), peripheral nervous system (schwannoma), and other tumors (for example, malignant mesothelioma). This protein represents a novel type of tumor suppressor gene the function of which is incompletely understood but which has been shown to hold significant homology to the 4.1 superfamily of cytoskeleton-associated proteins, specifically the ERM proteins. A primary known function of ERM proteins is found in linkage of transmem-
brane proteins to cytoskeletal actin filaments through the presence of a specific actin-binding domain. In line with this role, this family of proteins is thought to contribute to the processes of cell migration, endocytosis, and transmembrane signaling through alteration of the cytoskeletal apparatus. However, the ERM proteins are also known to achieve proliferative effects through Ras-mediated signaling, opposite to the tumor suppressor role attributed to merlin. Merlin is known to be present in two primary splice variant isoforms encoding peptides of 595 and 590 amino acids, respectively. The 595–amino acid version is capable of forming intramolecular bonds between the amino and carboxyl termini, in a manner inversely dependent upon phosphorylation status. D Dephosphorylation promotes circularization and catalytic activation, whereas phosphorylation inhibits merlin activity. Neither isoform has an actin-binding domain, but the 590–amino acid variant is capable of interacting with βIII-spectrin, an adapter protein that mediates merlin binding to actin. The 595–amino acid variant has been posited to exert multiple effects that combine to oppose cellular proliferation and oncogenesis.

Supporting the tumor suppressor role of merlin, the results of in vitro studies have demonstrated that reexpression of merlin in NF2– cells is capable of arresting the cell cycle at G1/G0. This finding is corroborated by other findings indicating that merlin is able to suppress the expression of a critical mediator of the cell cycle, cyclin D1, at least in part through inhibition of Pak-dependent signaling. Nevertheless, the direct effects of merlin appear to be more proximal, affecting Ras and Rac mediated signaling pathways, albeit in a fashion that is mechanistically distinct from the action of neurofibromin. The results of in vitro studies have demonstrated that merlin overexpression is capable of inhibiting cell proliferation and anchorage-independent growth mediated by the Ras protein. Further, the membrane-ruffling phenotype of schwannoma cells, a cytological marker of tumorigenic transformation, can be reversed when the Rac isoform Rac1 is inhibited or when merlin expression is restored. Morrison et al. have demonstrated, however, that merlin is capable of simultaneously inhibiting both Ras- and Rac-mediated signaling. Specifically, merlin inhibits activation of Rac and Ras by preventing exchange of GDP for GTP. The authors postulated that inhibition occurred through one of three mechanisms: sequestration of a GDP dissociation inhibitor, inhibition of the catalytic or associative functions of GEF with Ras and Rac, or activation of Ras and Rac GAP activity. The former two options are empirically supported as merlin has been demonstrated to associate with RhoGDI and Ral-GDS, a GDP dissociation inhibitor and a GEF protein that act downstream of Ras and Rac, respectively. Interplay between Ras- and Rac-mediated signaling underscores the importance of merlin function at the levels of Ras and Rac. The Ras/Rac-mediated activation of downstream Mek kinases requires prior phosphorylation by Rac, which may be activated by either Ras-dependent or Ras-independent mechanisms. Inhibition of Rac/Pak signaling has also been demonstrated through merlin-mediated inactivation of PI3K. Merlin, which has also recently been shown to be stabilized by the presence of an adapter protein, NGB, is inactivated through Rac/Pak-mediated signaling by phosphorylation. In contrast, activation through dephosphorylation is at least in part achieved through the action of MYPT-1-PP1-δ, a myosin phosphatase. Myosin phosphatase activity is stimulated in part through CD44 transmembrane protein activation, providing a mechanism by which cell–cell contact may achieve growth inhibition. These findings strongly support a tumor suppressor role for merlin through interaction with Rac- and Ras-mediated signaling in mutually inhibitory roles; however, additional data indicate that this protein may serve other roles in preventing cellular transformation.

In parallel with the wealth of data that implicate merlin as the culpable agent responsible for cell transformation mediated by Ras- and Rac-dependent pathways, alternative findings support the contribution of less canonical pathways. Merlin tumor suppressor activity has recently been associated with mitogen cell surface signaling receptor regulation in conjunction with another protein, Expanded. In tandem, these proteins have been shown to contribute to the Hippo signaling pathway, achieving additional regulatory effects on cellular proliferation. Deficiency of merlin has also been demonstrated to contribute to destabilization of intercellular cadherin-containing junctions. Additionally, merlin has been shown to interact with and inhibit a transactivation-responsive RNA-binding protein, thereby achieving a regulatory effect on cellular proliferation. Although the concerted physiological mechanisms and pathways that enmesh merlin-related signaling have yet to be fully elucidated, a considerable quantity of data implicates significant Ras- and Rac-dependent and independent contributions that may provide multiple, varied targets amenable to therapeutic intervention. A summary of the potential tumor suppressor roles of merlin is provided in Table 1.

**Mechanisms for Tumor Development.** Cellular transformation to schwannoma requires homozygous loss at the causative NF2 gene locus. However, in contrast to the situation regarding NF1 and neurofibroma development, an NF2– genotype alone appears to be both necessary and sufficient to precipitate schwannoma development. As in neurofibroma transformation, LOH represents the predominant mechanism responsible for tumor development. However, mutations in nonexpressing genomic regions affecting expression levels have also been observed, specifically with regard to hypermethylation. The results

<table>
<thead>
<tr>
<th>TABLE 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Putative Merlin tumor suppressor roles</strong></td>
</tr>
<tr>
<td><strong>Specific Role</strong></td>
</tr>
<tr>
<td>exchange of GDP for GTP</td>
</tr>
<tr>
<td>exchange of GDP for GTP</td>
</tr>
<tr>
<td>inactivation of PI3K-EC, a PI3K activator</td>
</tr>
<tr>
<td>growth arrest in Hippo tumor suppressor pathway in conjunction w/ related protein, “Expanded”</td>
</tr>
<tr>
<td>inactivation of oncogenic transcription factor</td>
</tr>
<tr>
<td>maintenance of cell–cell contact</td>
</tr>
</tbody>
</table>
of current studies do not support a critical contribution of the local microenvironment to oncogenesis. Early attempts to generate an NF2\textsuperscript{−/−} mouse model failed due to the requirement of the merlin protein product for embryonic development.\textsuperscript{98} Similar studies examining a heterozygous genotype display a significantly more severe phenotype than is observed in humans, with widespread tumor involvement and considerable progression to malignancy. However, Cre-lox–mediated conditional expression small animal studies, similar to those described above, have largely recapitulated the human disease phenotype, with notable Schwann cell hyperplasia and schwannoma development.\textsuperscript{43}

Progression Pathways—Development of Malignancy

The previous discussion has centered on mutations of the known genes responsible for development of neurofibromas and schwannomas, both when idiopathic and when in the context of the systemic neurogenetic conditions NF1 and NF2. Between one half and two thirds of malignancies related to these conditions occur in patients with NF1,\textsuperscript{56,72} whereas schwannomas have been documented to undergo malignant progression only rarely.\textsuperscript{161} In patients with NF1, malignancies most commonly arise from plexiform neurofibroma variants. Approximately 30 to 40% of patients with NF1 manifest plexiform tumors in the major nerve trunks, and approximately 10% of these tumors will undergo progression to malignancy.\textsuperscript{37} Although MPNSTs only occur in a minority of patients with NF1 and a considerably smaller number of individuals in the general population (.001%),\textsuperscript{32} malignant progression represents a warranted cause for concern given the expected prognosis with current therapies. The connection between NF1 and malignancy is of prognostic significance since NF1-related MPNSTs are diagnosed at a younger age (median 26 compared with 62 years of age) and are associated with a lower 5-yr survival rate compared with those occurring sporadically (21% compared with 42%).\textsuperscript{10} These statistics underscore both the inadequacy of current therapeutic strategies for MPNSTs, which are incapable of achieving a cure, and the need for a more detailed understanding of the molecular mechanisms that support malignant progression.

Difficulty in isolating a consistent molecular mechanism for malignant progression appears to be related to the multilayered heterogeneity found through analysis of both tumor samples and isolated tumor cell lines. In a series of 30 patients with MPNSTs and NF1, NF1 mutations were detected in 27 patients, but neither an association between the mutation type and clinical severity nor a conserved NF1 mutational event was discovered.\textsuperscript{154} Further, the authors were unable to corroborate previous finding of a large intragenic 1.5-Mb deletion as a prognostic contributor.\textsuperscript{26} Nevertheless, results from animal models suggest a role for both the NF1 and TP53 genes, in tandem. Mice engineered as compound heterozygotes of both genes were found to recapitulate malignant peripheral nerve tumor development found in humans, with observed loss of both wildtype alleles and full penetrance,\textsuperscript{20,155} but the results of further investigations have indicated that there may be fundamental differences, regarding the roles of NF1 and TP53, between sporadic and NF1-associated malignancies. Birindelli and colleagues\textsuperscript{12} noted a significantly higher loss of TP53 heterozygosity in association with NF1. Others have failed to corroborate the finding of an elevated TP53 mutation rate in afflicted patients with NF1,\textsuperscript{70,99} while increased nuclear accumulation of the p53 protein has also been implicated.\textsuperscript{65,97} Equipoise exists within the current literature regarding the role of the p53 protein in malignant progression. Nevertheless, several additional cell cycle regulators have been implicated as potential contributors to the process of malignant progression.

A comparison of microarray data from eight MPNST-derived cell lines and seven normal Schwann cell lines supports a heterogeneous range of expression for multiple cell cycle proteins—including: p16INK4A, p53, p14Arf, and pRb—serving tumor suppressor roles.\textsuperscript{101} The authors also noted consistent expression of the EGF receptor and S100β, with concomitant downregulation of Schwann cell differentiation markers and upregulation of neural crest stem cell markers, Sox9 and Twist1. In the context of the same study, data from 45 MPNSTs indicated the presence of a 159 gene “expression signature” sequences unique to the MPNSTs. In the subset of five patients who had NF1, the authors demonstrated loss of p16INK4A (also called CDKN2A). In partial corroboration, Birindelli et al.\textsuperscript{12} noted depression of p16INK4A independent of NF1 status. Miller et al.\textsuperscript{101} were subsequently unable to detect an expected alteration of Rb phosphorylation status or expression in MPNST, questioning the relevance of prior findings indicating a reduction in p16INK4A. In a separate assessment of 12 MPNSTs, loss of Rb expression was noted in two tumors and LOH was noted in an additional four, half of which were associated with NF1.\textsuperscript{97} Corroborating the data generated by Miller et al., S100β\textsuperscript{147} and additionally nestin\textsuperscript{141} have been validated (separately) as diagnostic markers of MPNST. However, other findings implicate non–cell cycle signaling pathways and cellular mechanisms in the process of malignant progression.

Aside from the contribution of specific NF1-associated and cell cycle regulator mutations to malignant progression, components of mitogenic signaling pathways separate from those required for oncogenesis have been implicated, as have elements responsible for immune recognition. The PDGF receptor and fibronectin represent additional proteins that are commonly present in benign neurofibromas but are significantly upregulated in the MPNST.\textsuperscript{28} The authors of multiple studies have concluded that the EGF receptor is also upregulated in MPNST tissue in comparison with normal human Schwann cells. The EGF receptor represents a mitogenic signaling receptor that is upregulated in MPNSTs and is upregulated in at least a subset of cells within benign neurofibromas.\textsuperscript{28} This receptor is homologous to the receptors of the erBβ class that are expressed in normal human Schwann cells, are responsive to neuregulins, and have been shown to be constitutively phosphorylated in MPNSTs. Blockade of both receptor types appears to depress the invasive potential of these tumors. Further, a putative link between the EGF receptor and invasive potential has been posited through a link with CD44. Sherman et al.\textsuperscript{159} initially discovered that CD44, a transmembrane protein implicated in cell–cell adhesion, migration, growth factor signaling, and metastasis, is aberrantly overexpressed in MPNSTs but not in benign neurofibromas. This CD44 upregula-
tion appears to be largely independent of Ras-mediated signaling and contributes to the invasiveness of the MPNST in a manner at least partially dependent upon the Src-mediated intracellular signaling pathway. The discovery of an EGF-responsive element in the CD44 promoter provides evidence for the presence of dysregulated EGF-mediated signaling as a contributor to this process. Further, CD44 upregulation has been linked to enhanced neuregulin-mediated signaling, indicating a potential for the role of a positive feedback mechanism.

Evasion of immune surveillance has also been implicated in the progression toward malignancy. Data supporting this hypothesis derives from a large-scale profiling of gene expression in an MPNST-derived tumor cell line. Downregulation of immune function–related genes, including genes that produce a transcription factor (MHC2TA), an antigen processing protein (TAP1), and a chaperone protein involved in antigen processing (CD74), may confer an additional survival advantage to transformed cells that are in the process of malignant invasion. Together, these data support the conclusion that multiple cell cycle regulators, mitogenic signaling pathways, and evasion of immune surveillance may contribute to the process of malignant progression, yet consistently divergent findings have prevented a unified understanding of the definitive roles of these contributors.

**Experimental Therapeutic Strategies**

The current paradigm for the treatment of benign schwannomas and neurofibromas, as well as MPNSTs, centers on resection and extends to the use of adjunctive treatments for postoperative management, including the use of chemo- and radiotherapies. In the context of treating single or isolated lesions, as occurs in the absence of a germline mutation, microsurgical resection may achieve preservation or recovery of neurologic function largely related to relief of compression on eloquent neural structures. In the case of benign tumors, maintenance or improvement of neurological function is most often seen with schwannoma resection. In cases of plexiform neurofibromas, complete tumor resection is often not feasible; instead, tumor debulking and multimodal postoperative management strategies are required. Inability to achieve complete tumor resection poses particular concern in cases of plexiform neurofibroma, given the propensity of these tumors for malignant progression. The high level of invasiveness and metastasis observed in MPNSTs, when coupled with the difficulty of achieving complete resection with microsurgical technique and the suboptimal sensitivity of these tumors to adjunctive treatments, provides the context for current expectations of a poor prognosis. The development of novel therapeutic agents is particularly justified as a means to augment the currently available treatments for NFI-associated lesions. Recent advances in understanding of the molecular mechanisms subserving tumor formation and malignant progression provide the potential for targeted, pathway-specific interventions. In particular, we will discuss currently available off-label therapeutic agents that may yet demonstrate benefit in the treatment of MPNSTs and will broadly distin-

**Modification of the Tumor Microenvironment**

The complex microenvironment of the neurofibroma appears to be intricately intertwined with the process of tumor formation, providing multiple parallel opportunities for therapeutic intervention that have the potential to impact both the transformation process and the progression to malignancy, without directly impacting the fundamental dysfunctional processes implicated within the Schwann cell. Specifically, targets within the microenvironment include: mast cells, neoangiogenesis, and tumor-related fibrosis. In addition to altering the tumor phenotype, modification of the microenvironment holds the potential to generate a milieu that is less permissive to further tumorigenesis or malignant progression.

**Mast Cell Inhibition.** As discussed previously, the NF1 heterozygote mast cell plays a significant role in the process of neurofibroma-related tumorigenesis, due in part to increased levels of SCF in the local microenvironment, which promote hypermotility, hyperproliferation, and chemotaxis to the tumor microenvironment. In turn, mast cell–mediated signaling is thought to promote further SCF secretion, fibrosis, and angiogenesis through release of its own mediators. To date, the only clinical trials designed directly to inhibit mast cell function used ketotifen fumarate, an antihistamine that helps to stabilize mast cells and prevent degranulation. Patients in the first trial reported subjective improvements in quality of life and decreased pruritus, pain, and tenderness. In terms of effect on tumor size and growth, the results were reported to be consistently positive although less uniform. A second trial corroborated the observed improvement in symptomatology but failed to examine effect on tumor size.

Because the mast cell appears to acquire a pivotal role in coordinating the positive feedback mechanisms of Schwann cell hyperplasia, neovascularization, and fibrosis, therapeutics targeted to the processes of their recruitment and activation hold promise in future attempts at therapeutic intervention. Recruitment to the local neurofibroma microenvironment has been demonstrated to require αβ3-integrin attachment to the endothelial VCAM-1 receptor. Natalizumab (Tysabri), a monoclonal antibody initially pioneered for its ability to prevent leukocyte migration to demyelinating plaques in patients with multiple sclerosis through inhibition of αβ3-integrin, was demonstrated to significantly improve outcomes in these patients but was voluntarily withdrawn from studies due to its potential contribution to development of progressive multifocal leukoencephalopathy. However, authors of subsequent studies have concluded that predisposition towards development of progressive multifocal leukoencephalopathy was probably present due to the unique milieu occurring during the pathogenesis of multiple sclerosis and was not directly related to the effects of natalizumab. In a similar fashion, inhibition of mast cell migration may be expected from downregulation of...
VCAM-1 expression. Tumor necrosis factor—α (TNFα) is known to stimulate VCAM-1 expression, so use of known inhibitors of TNFα, such as the monoclonal antibodies infliximab (Remicade) and etanercept (Enbrel), may merit exploration as therapeutic options. These agents currently represent therapeutic alternatives in chronic inflammatory conditions such as Crohn disease and ulcerative colitis. Since high levels of SCF are thought to play an important role in mast cell activation, either inhibition of SCF or blockade of its receptor, c-kit, also represents a therapeutic alternative. Several potential small molecule and antibody-based inhibitors of SCF and c-kit have been described as potential treatments for allergic inflammation and warrant examination for possible effects on the local microenvironment within the neurofibroma and MPNST. Imatinib mesylate (Gleevec) was originally designed to exert effect on the bcr-abl signaling pathway, crucial to development of chronic myelogenous leukemia, through interaction with the PDGF receptor. It has since been demonstrated to inhibit c-kit activation and is currently being tested for its therapeutic potential in other malignant diseases.

Inhibition of Fibrosis. Prevention of mast cell recruitment and activation represent attractive therapeutic endpoints because the mast cell appears to assume both a central and upstream role in the genesis of the tumor microenvironment. Nevertheless, the downstream processes of fibrosis and neovascularization, both observed during tumorigenesis and exacerbated during malignant progression, also represent relevant targets. Pirfenidone, an antifibrotic agent that inhibits fibroblast function by modulating the effect of growth-inducing cytokines, has been tested as a treatment for patients with NF1 and neurofibromas. In a Phase II study of 24 patients, four patients had a greater than 15% reduction in tumor volume, the condition of 17 remained unchanged, and three experienced tumor progression to malignancy over a 24-month treatment period (17 patients were treated for the entire period). Volume assessment was performed using 3D magnetic resonance imaging. Other agents—including HMG-CoA reductase inhibitors (statins), penicillamine, colchicine, and angiotensin-converting enzyme inhibitors—have been examined for their ability to reduce or reverse collagen deposition in separate in vitro studies. None have yet been systematically examined for their abilities to impact the fibrotic microenvironment in the context of neurofibroma or MPNST treatment. Additionally, interferon-γ has been demonstrated to reduce fibroblast activation and proliferation, potentially countering the effects of endogenous mediators such as TGFβ. Multiple in vitro experiments by Nakayama et al. have demonstrated the ability of transfected interferon-γ to inhibit proliferation of both isolated neurofibroma and MPNST110 cell lines. Further, administration has demonstrated effect in clinical trials of idiopathic pulmonary fibrosis.

Inhibition of Neovascularization. Tumor neovascularization represents a growth requirement beyond an upper diameter of a few millimeters. Studies have corroborated the increased density of vascularity at the microscopic level in the neurofibroma and MPNST, despite the gross pale appearance that is often observed. To date, thalidomide represents the only agent that has been examined in the context of a Phase I clinical trial for the treatment ofplexiform neurofibromas, specifically for the treatment of neovascularization. In an open-label trial involving 20 patients, doses of up to 200 mg/day were tolerated, and the worst adverse event, mild peripheral neuropathy, was transient and occurred in two individuals. Four of the 20 patients noted a reduction in tumor size of less than 25% as assessed by MR imaging or computed tomography at a 12-month follow-up time point after therapy initiation. Preclinical studies have focused on targeting specific cell types and molecular mediators implicated in the process of neovascularization. The neurofibromin-deficient Schwann cell is the prime contributor to neovascularization, with a shift in the balance of secreted mediators depending upon whether or not both alleles at the NF1 locus are intact, but infiltrated mast cells are known to contribute angiogenic mediators such as VEGF. We have previously discussed that FGF-2, MK, and PDGF secretion are upregulated in the neurofibromin-deficient Schwann cell. Each of these angiogenic mediators, FGF-2, MK, PDGF, and VEGF all have the capability to bind heparin. Midkine has also been shown to be inhibited by a separate glycosaminoglycan, chondroitin sulfate E. The potential to achieve direct inhibition of single mediators has been demonstrated in clinical trials of the anti-VEGF monoclonal antibody bevacizumab (Avastin) in unrelated conditions. The results of animal model studies, however, have demonstrated that the same result could be achieved using an anti-VEGF immunogen as a vaccine, abolishing concern for generation of a systemic immune reaction that may occur with antibody injections. Alternatively, gene-based approaches to inhibit VEGF have recently demonstrated promise. One such approach utilized an adenovirus-mediated delivery strategy to simultaneously achieve tumor cell oncolysis and inhibition of VEGF signaling. Inhibition of individual angiogenic factors may be overcome through alteration in the balance of tumor cell receptor expression and possibly through the use of alternate signaling pathways. Therefore, the use of a single agent that simultaneously blocks multiple mediators holds increased promise in achieving reduced neovascularization. However, direct inhibition of the aforementioned angiogenic mediators by heparin alone has not demonstrated efficacy. In an animal model in which human nerve sheath tumors are removed from patients and implanted into the subrenal capsule of female athymic mice (nu/nu), the tumors were histologically indistinguishable from human tumors. Using this animal model, the researchers found that treatment with heparin alone resulted in an increase in tumor vascularity that correlated with an increase in tumor size. Use of hydrocortisone alone failed to achieve an effect. Yet, coadministration of heparin and hydrocortisone resulted in simultaneous decreases in neovascularization and tumor size. This dependence of effect on hormone status has been corroborated in breast cancer studies. Simultaneous administration of heparin with tamoxifen, a partial estrogen antagonist, achieved a more demonstrable effect than either alone. Alternative strategies for inhibition of neovascularization include inhibition of individual angiogenic receptors and direct prevention of proliferation. A variety of inhibitors have been investigated in the...
attempt to attenuate receptor activation. The most biologically relevant VEGF receptor appears to be VEGFR-2. The VEGFR-2 inhibitors that have been assessed include neutralizing antibodies, ribozymes directed to this receptor, antisense strategies, and small molecule inhibitors. Additionally, strategies have been attempted to directly inhibit endothelial cell proliferation. Treatment with proliferation inhibitors, such as TNP-470, has been shown to decrease tumor vascularity and size more than treatment with placebo in the athymic mouse model, described earlier in this section. Finally, the process of neovascularization encompasses its own microenvironment, with signaling between pericytes and endothelial cells playing an important role in angiogenic sprouting and tube formation. Multiple studies have shown that inhibition of pericytes may also serve as a means to limit neovascularization, in the treatment of both neurofibromas and MNPSTs as well as other malignancies.

Schwann Cell–Specific Approaches

While strategies aimed at the tumor microenvironment largely focus on slowing invasiveness or growth potential or disrupting the self-perpetuating trophic support feedback cycle, therapeutics targeted to the Schwann cell represent a more direct approach by which to halt or reverse the causative mechanisms underlying initiation and maintenance of processes responsible for transformation and malignant progression. However, the majority of Schwann cell–specific therapeutic approaches operate by manipulating cell-surface receptors specialized for transduction of mitogenic signals or by modulating the function of contributory intracellular signaling pathways. The targeting of EGF and PDGF receptors represent the predominant strategies for inhibiting transmembrane signaling receptors. Conversely, strategies designed to disrupt intracellular signaling pathways interact with Ras production, components of the Ras pathway, or downstream effectors.

Directed Therapeutics for Cell-Surface Mitogen Receptors

Upregulation of physiologically relevant transmembrane cell surface receptors associated with intracellular mitogen signaling cascades is a common finding in tumors that have undergone clinical progression to malignancy. Specifically, evidence to indicate upregulation of the EGF and PDGF receptors has been previously cited. Because both are receptor tyrosine kinases that act as first steps within various Ras-mediated signaling cascades, their blockade represents an attractive therapeutic target. Preclinical studies have demonstrated that blockade of the EGF receptor–related erbB receptors with PD168393 and PD158780 have blocked proliferation of MPNST cells in an in vitro setting. The utility of direct EGF receptor blockade with gefitinib (Iressa) as a potential therapeutic end point for MPNST treatment has also been demonstrated in an in vitro setting. In addition to having been demonstrated in preclinical and clinical studies for the treatment of a wide variety of cancers, EGF receptor blockade has been extended into the clinical context for treatment of MPNSTs. In a recently published abstract, Albritton et al. examined erlotinib as a therapeutic approach for treatment of unresectable or metastatic MPNSTs. Of 24 enrolled patients, 20 were deemed eligible for treatment. At a median survival of 4 months, no demonstrable effect on progression was noted, and one patient was noted to have stable disease. Accrual of patients into the trial was halted because of the lack of objective evidence of treatment effect. Although a clinical trial for treatment of MPNST through PDGF receptor inhibition has not been reported, this receptor has been identified as a potential contributor to tumor progression and so represents a potential therapeutic target.

Directed Therapeutics for Intracellular Signaling Pathways

The Ras protein undergoes posttranslational modification with the ultimate result of achieving membrane attachment. The cysteine residue closest to the carboxyterminus is joined with a 15-lipid moiety, a farnesyl group. Following prenylation, the three remaining residues are cleaved, and carboxymethylation occurs at the same cysteine residue. Following the addition of the farnesyl lipid moiety, the Ras protein undergoes addition of separate lipid moieties, either achieving palmitoylation in the H-Ras or N-Ras isoforms or addition of a poly-L-lysine (polybasic) motif in the K-Ras4B isoform. This results in targeting to separate cell membrane microdomains and in the use of distinct intracellular recycling pathways. Further, each isoform is known to preferentially interact with subsets of known downstream effectors. H-Ras appears to preferentially activate PI3K, whereas K-Ras4B interacts more readily with Raf and Rac. Although the fundamental roles of the distinct lipid moieties present on different Ras isoforms have yet to be fully discerned, therapeutic strategies designed to broadly manipulate Ras prenylation have been explored under the assumption that inappropriate subcellular localization will negatively impact Ras-mediated signaling.

Ras Prenylation Inhibitors

The 15-carbon farnesyl group attached to the carboxyl cysteine is generated through the biosynthetic pathway responsible for cholesterol formation. The rate-limiting enzyme within this biochemical cascade, HMG-CoA reductase, is inhibited by the statin family of pharmacological agents. Because the cholesterol biosynthetic pathway is also important for the production of multiple lipid- and cholesterol-based derivatives required for cell growth and mitogenesis, statins have been demonstrated to negatively impact multiple aspects of tumorigenesis. Preclinical data have indicated that simvastatin can reverse the malignant progression of a fibroblast cell line following constitutive expression of a Ras oncogene. Further, an effect of simvastatin has been demonstrated in an in vitro setting. PD158780 have blocked proliferation of MPNST cells in a fibroblast cell line following constitutive expression of a Ras oncogene. Although the current literature does not specifically examine the potential utility of statins for the treatment of benign or malignant peripheral nerve tumors, lovastatin has been demonstrated to reduce cognitive impairment and to inhibit Ras-mediated signaling in a mouse model of NF1. The broad intracellular effects of cholesterol and lipid moieties indicates that statins probably have a much broader role in inhibiting tumor formation or malignant progression than through Ras alone.

Targeting of farnesyl transference represents the second major method whereby the inhibition of prenylation has been approached. Farnesyl transference inhibitors prevent attachment of the 15-carbon lipid moiety to the Ras carboxyterminus. Because dysregulation of Ras signaling occurs in multiple cancers, FTIs have been explored in...
preclinical and clinical contexts as treatment strategies for multiple benign and malignant tumors, including those of Schwann cell origin. Evidence has suggested utility in a variety of xenograft cancer models, including models of hematological, head and neck, ovarian, lung, colon, breast, bladder, and prostate cancer and melanoma.\cite{4,9,10} Findings related to nerve sheath tumors include the demonstration that FTIs have the capability to significantly reduce hyperproliferation and clone formation in NF1-deficient mice that demonstrated significantly increased proliferation after administration of forskolin, an activator of adenylate cyclase. Subsequent treatment with an FTI (L-739749) significantly reduced hyperproliferation but not invasiveness, leading the authors to postulate the potential utility of FTIs for benign nerve sheath tumors.\cite{66,67} Prior to the publication of these findings, Yan et al.\cite{67} had demonstrated that treatment of an MPNST-derived cell line, ST88-14, resulted in loss of many phenotypic characteristics of malignancy, with the cell line becoming contact-inhibited, flat, and non-refractile and losing the capability to grow in soft agar. Further, treated cells were incapable of associating Ras to the inner leaflet of the cell membrane. A Phase I clinical trial assessing FTI (tipifarnib) monotherapy has recently been completed. Pediatric patients 2 to 18 years of age, with either solid tumors or NF1-related plexiform neurofibromas, were treated with tipifarnib. Average farnesyl transferase activity was reduced to 44\% (median 35\%) of baseline in a manner that could not be correlated with the assessed dosing regimen.\cite{19,39} Although the study generated dose-ranging safety data that have served as the basis for a subsequent Phase II trial (National Cancer Institute protocol ID NCT00021541), lack of observed response, including in the patients with plexiform neurofibromas, is in line with the results observed in use of FTIs in clinical trials for other cancers.\cite{118,119,120,121} A potential reason for the poor clinical results obtained with FTI monotherapy may be related to the inability of FTIs to block membrane association of the K-Ras or N-Ras isoforms—that is, the limitation of their blocking to the association of H-Ras. The K- and N-Ras isoforms are capable of undergoing geranylgeranylation when farnesyl transferase is inactivated, a compensatory reaction that functionally substitutes for farnesylation. Further, Mattingly et al. have demonstrated that K- and N-Ras isoforms represent the predominant isoforms observed in human NF1 cell lines.\cite{30,36} Alternative strategies to prevent Ras prenylation are under investigation, including inhibition of geranylgeranyl transferase,\cite{118} Ras converting enzyme, and carboxymethylase.\cite{30} Much as with the attempts to use statins to prevent biosynthesis of lipid moieties, inhibition of prenylation can be expected to exert a wide range of intracellular effects, as it represents a broad cellular strategy for membrane anchorage.

Direct Ras Inhibition Strategies. Several techniques, including Ras prenylation, have been designed to modulate the dysregulation of intracellular pathways observed in peripheral nerve tumors. One such alternative approach designed to directly achieve Ras inhibition has been accomplished through use of farnesylthiosalicylic acid, an agent that inhibits all Ras isoforms by competing with Ras-GTP for saturable binding sites in the cell membrane.\cite{7} The same authors demonstrated reversal of the transformed phenotype and tumor growth inhibition in multiple MPNST cell lines, including ST88-14, S265P21, and 90-8.\cite{7} Alternatively, reconstitution of the neurofibromin GRD has demonstrated promise in multiple preclinical contexts. Hiatt et al.\cite{80} achieved normalization of growth and Ras-Erk signaling in transformed NF1-/- mouse fibroblast and hematopoietic cells. Most recently, Thomas et al.\cite{81} have demonstrated that stable retroviral delivery of the GRD to human NF1-/- Schwann cells is capable of reducing Ras activation by 16 to 33\% and the proliferation of the cells by 53\%. Nevertheless, in vitro angiogenic potential was not inhibited, indicating only partial reversal of the transformed phenotype. Expression of either the NF1 gene or the GRD-related region of this gene in a colorectal cancer cell line with oncogenic K-Ras was capable of suppressing tumor formation in vitro.\cite{82} The neurofibromin GRD reduces the ability of the NIH 3T3 NF1-deficient fibroblast and hematopoietic cell lines to form colonies in an in vitro environment.\cite{83} Further, depression of K-Ras and N-Ras activity, in association with inhibited proliferation of acute myeloid leukemia cells has been demonstrated through expression of the neurofibromin GRD in cells deficient for this protein.\cite{102} Preclinical studies have also examined modulation of related downstream signaling effector pathways. Targeting Signal Transduction Pathways. Merlin was previously discussed as playing a tumor suppressor role through prevention of Ras activation. Activated through Ras-dependent and -independent mechanisms, Rac plays a central role in further activation of the Ras pathway through Pak-mediated phosphorylation of downstream Rac effectors. Both overexpression of merlin and provision of dominant negative Pak have been examined as strategies to reverse the transformation process, at least partially through modulation of elevated Ras-mediated signaling. Merlin overexpression has been demonstrated to reverse transformation in an NIH 3T3 fibroblast cell line transfected with an oncogenic variant of Ras.\cite{103} Additional studies have indicated effects extending to downstream effector pathways.\cite{65,85} Dominant negative Pak mutants, delivered by stable retroviral transduction, have been demonstrated to potently inhibit the transformation process in both rat Schwann cells and in an MPNST cell line derived from a patient with NF1.\cite{146} In alternative approaches, investigators have explored direct inhibition of downstream signal transduction pathways. Mattingly et al.\cite{86} have recently demonstrated the antiproliferative effects of multiple Erk1/2 MAPK inhibitors PD98059, PD184352, and U0126, in three MPNST cell lines. Both PD98059 and PD184352 demonstrated cytotoxicity when applied to tumor cells, whereas U0126 demonstrated a cytostatic result. Only PD184352 significantly reduced Erk1/2 MAPK activation, but it simultaneously promoted apoptosis in a control rat Schwann cell line, suggesting that demethylating peripheral neuropathy could limit its therapeutic potential. Separate in vitro\cite{106} and in vivo\cite{106} studies of varied cancers have examined Erk inhibition with sorafenib, a multikinase inhibitor; the results have demonstrated the capacity to inhibit angiogenesis, to reduce cellular proliferation, and induce apoptosis. The wide range of effects was thought to be due to the promiscuity of sorafenib, as it is known to inhibit the function of

---

**Neurosurg. Focus / Volume 22 / June, 2007**

**J. Riley, A. Spiotta, and N. Boulis**
multiple receptor tyrosine kinases, in addition to inhibiting Erk.

Inhibition of PI3K/Akt-mediated signaling has been attempted through reduction of substrate for PI3K and through the use of agents that act at both PI3K and at Akt. A tumor suppressor gene mutated in several cancers, PTEN, is responsible for breakdown of phosphatidylinositol (3,4,5)-triphosphate, an activator of Akt and the enzymatic product of the interaction of phosphatidylinositol (4,5)-bisphosphate and PI3K. Adenoviral-mediated overexpression of PTEN has been employed in both in vitro and in vivo studies for the treatment of bladder cancer and colorectal cancer. Classic research-oriented inhibitors of PI3K include wortmannin and LY294002. The former covalently binds the catalytic subunit of PI3K, and the latter competes with ATP for the ATP binding site. Not only has LY294002 been shown to reduce in vitro MPNST cell growth following EGFR receptor stimulation, it has also been shown to have the capability to sensitize a variety of tumor cell types (for example, prostate adenocarcinoma, renal adenocarcinoma, bladder carcinoma, and colon carcinoma cells) to apoptosis in the presence of a microtubule destabilizing agent. The clinical usefulness of both LY294002 and wortmannin has, however, been limited by their solubility and stability. A rationally derived wortmannin derivative, PWT-458, has been reported to potently inhibit PI3K in xenograft tumors (for example, gliomas, non–small cell lung cancers, and renal cell carcinomas) grown in nude mice with better therapeutic index than wortmannin. A separate compound, PX-866, has been demonstrated to have broad-spectrum PI3K inhibitory capacity and has demonstrated antitumor capacity in severe combined immunodeficiency mouse models, increasing the effects of both cisplatin and radiation. Also known as protein kinase B, Akt has 53% homology with protein kinase C and 47% homology with protein kinase A, which places a premium on the use of rational drug design to generate an Akt-specific agent. Generation of structure-based inhibitors has produced Akt-selective agents that are pharmacokinetically and pharmacodynamically stable, but recognition that the three known Akt isoforms may play distinct roles in oncogenesis has prompted an acknowledgment that isoform-specific agents may be required. Finally, the absence of functional neurofibromin has been implicated as a cause for constitutive activation of tuberin and mTOR, both downstream effectors of PI3K/Akt, as described previously. Rapamycin and related agents have been demonstrated to significantly inhibit signaling through this pathway. Downstream inhibition of the numerous conserved molecular effectors of these pathways controlling cellular growth, proliferation, survival, and apoptosis has been explored because these agents are valuable both as research tools and as potential cancer therapies for a broad range of conditions.

Schwann Cell–Specific Oncolytic Approaches. Schwann cell–specific oncolysis represents a unique therapeutic paradigm in the spectrum of peripheral nerve tumor treatment strategies. Delivery of a viral vector as an anticancer agent has been hypothesized to achieve effect through direct oncolysis, induction of antitumoral immunity, and chemo- or radiosensitization. The ability to achieve viral tropism for tumor cells represents a novel approach to specifically target rapidly dividing tumor cells while sparing the surrounding quiescent parenchyma. Such tropism was initially thought to result from an alteration of interferon-mediated antiviral responses stemming from dysregulated Ras-mediated signaling. However, evidence for uptake into MPNST cell lines that either did or did not display dysregulated Ras signaling but not into normal human Schwann cells has provided the rationale for an alternate mechanism. This observation suggests that attenuated but still replication-competent viruses (oncolytic viruses) can be used to selectively kill tumor cells. Additional data now indicate a role for elevated PI3K-mediated signaling in oncolytic HSV tumor cell tropism. Broadly based strategies using this therapeutic approach to prevent clinical infection with are achieved by deletion of multiple viral genes required for replication in quiescent cells. Therefore, attenuated viral vectors become capable of replicating only in those cells that can supplement the action of the deleted genes. Because the enzymatic machinery of cell division is upregulated in rapidly dividing tumor cells, viral replication and oncolysis are constrained to this cell population. Deleted genes may include ribonucleotide reductase, a virulence factor (ICP34.5) important for protein translation, and multiple latency-associated genes. After initial demonstration that MPNST cells are permissive for multiple oncolytic HSV variants and undergo selective oncolysis as compared with normal human Schwann cells, Messerli et al. have demonstrated the antitumor effectiveness of an oncolytic HSV-based treatment in both xenograft transplant and dominant mutant NF2 mouse models. Mahler and colleagues have subsequently extended their previous results to the use of combination therapy by coadministration of oncolytic HSV with the angiogenesis inhibitor erlotinib. When the agents were administered individually, the oncolytic HSV was noted to have significant antitumor effects, whereas erlotinib-treated animals developed a trend toward tumor reduction. Although overall cell killing was higher in the animals that received both agents, an additive anti-MPNST effect was not noted. Simultaneous treatment with erlotinib did not inhibit the replicative or tumor cell killing capacity of the oncolytic HSV. Subsequent studies have examined incorporation of specific transgenes designed to augment the oncolytic HSV-mediated tumor cell killing capacity. Liu et al. have demonstrated that incorporation of the dominant-negative FGF receptor into an oncolytic HSV resulted in improved killing of both MPNST cells and endothelial cells as compared with the effect of oncolytic HSV alone or transfection with dominant-negative FGF receptor alone, when studied in vitro. The oncolytic HSV with dominant-negative FGF receptor demonstrated greater in vivo inhibition of angiogenesis and tumor growth than did an oncolytic HSV vector without the dominant-negative FGF receptor. A similar result was attained when Liu et al. used a separate transgene, platelet factor 4, specifically chosen for its known antiangiogenic effects. It is likely that subsequent research will explore mechanisms to improve viral tumor distribution and to place ICP34.5 under a tumor-specific promoter as well as to explore additional potential anti-tumor transgenes.
Conclusions and Future Directions

Current surgical therapy is largely effective for isolated neurofibromas and schwannomas. Near-term surgical advances will probably involve incorporation of minimally invasive methods of impeding tumor progression, which would permit the treatment of a larger number of suspicious lesions. Such a technique could also be applied to the difficult challenge of treating large plexiform neurofibromas in otherwise functional nerves. The current level of morbidity associated with resection together with the diffuse nature of NF1-related tumors prevents the elimination of risk for malignant transformation, indicating a need for therapeutic strategies capable of directly addressing the underlying mechanisms responsible for peripheral nerve tumor transformation and malignant progression. In the preceding text, recent progress in elucidation of the pathways of peripheral nerve tumorigenesis and malignant peripheral nerve tumor progression has been outlined. Recognition of the causative roles played by neurofibromin and merlin at the NF1 and NF2 loci has served a crucial role in further developing an understanding of the molecular pathogenesis of neurofibromas, schwannomas, and MPNSTs. Although intensive research is still required to fully unravel the putative initiation and progression mechanisms, the current level of understanding provides the framework necessary for the development of rational therapeutic agents designed to inhibit known contributors to both the initiation and progression pathways. Potential therapeutic avenues are varied, impacting both pathways directly related to the known causative mutation as well as elements of the surrounding microenvironment. It will be of significant importance, in the near future, to press forward in the attempt to target disparate components of the known and putative molecular pathways due in part to the potential for redundancy within implicated intracellular and extracellular signaling pathways. This is supported by the findings of current literature for treatment of other malignancies in which Ras-mediated dysregulation is thought to play a central role, where efforts to target individual components alone have yet to generate a curative approach. Therefore, near-term future therapies attempted with curative intent will probably still require multimodal therapeutic intervention.

References

28. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH: Pro-
Experimental therapeutic approaches to peripheral nerve tumors


75. Le LQ, Parada LF: Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. *Oncogene* epub ahead of print, 2007
87. Lu J, Rangwala F, Ratner N, Cripe TP: Malignant peripheral nerve sheath tumors with high and low Ras-GTP are angiogenic and invasive and can be induced to hyperproliferation by introduction of an exogenous NF1 gene. *Cancer Res* 56:2872–2876, 1996
Experimental therapeutic approaches to peripheral nerve tumors


114. Ozerdem U: Targeting of pericytes diminishes neovasculariza-


117. Ozerdem U: Targeting of pericytes diminishes neovasculariza-


133. Schulze KM, Hanemann CO, Muller HW, Hanenberg H: Transduction of wild-type Merlin into human schwannoma...


152. Trovo-Marqui AB, Tajara EH: Neurofibromin: a general out-


158. Weiss B, Bollag G, Shannon K: Hyperactive Ras as a therapeu-

159. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, et al: Phase I trial and pharmacokinetic study of the farnesyl-


166. Yan J, Roy S, Apolloni A, Lane A, Hancock JR: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-


J. Riley, A. Spiotto, and N. Boultis

Neurosurg. Focus / Volume 22 / June, 2007


Accepted April 30, 2007.

Address reprint requests to: Nicholas M. Boulis, M.D., Cleveland Clinic—Lerner Research Institute NB2-126, Department of Neurosciences and Center for Neurological Restoration, 9500 Euclid Avenue, Cleveland, Ohio 44195. email: boulisn@ccf.org.